MedTrace Logo

Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety

NCT02878928 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 579

Last updated 2016-12-19

No results posted yet for this study

Summary

A prospective, multi-center, randomized, subject and outcome evaluator blind , parallel-group study evaluating the effect of pharmacogenetic-guided versus standard of care treatment for subjects diagnosed with depression and/or anxiety disorders.

Conditions

Interventions

GENETIC

IDgenetix Neuropsychiatric Test Panel

The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.

Sponsors & Collaborators

  • Innovis LLC

    collaborator INDUSTRY

  • AltheaDx

    lead INDUSTRY

Principal Investigators

  • Joel Centeno · AltheaDx

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02878928 on ClinicalTrials.gov